ELIQUIS
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) announced on Aug 28, 2011 the main results of the Phase 3 clinical trial ARISTOTLE (Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation), which uated ELIQUIS
